Cameron Santoro

Cameron Santoro is an associate editor for The Center for Biosimilars®, The American Journal of Managed Care® (AJMC), and AJMC.com.


FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra

March 27, 2025

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for osteoporosis, bone metastases, and other bone-related conditions, amidst a flurry of similar approvals and legal settlements.

Biosimilar Natalizumab-sztn Shows Comparable Efficacy and Safety to Tysabri in RRMS

March 25, 2025

Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its potential as a cost-effective treatment option.